Literature DB >> 21314365

Comparison of antioxidant capacities of Ganoderma lucidum (Curtis) P. Karst and Funalia trogii (Berk.) Bondartsev & Singer by using different in vitro methods.

Hande Yegenoglu1, Belma Aslim, Feyza Oke.   

Abstract

The aim of the study was to investigate antioxidant activities of Ganoderma lucidum and Funalia trogii. Ethanol and water crude extracts from G. lucidum and F. trogii were investigated for their antioxidant capacity in some different assays, namely, the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity, metal chelating activity against ferrous ions, and plasma lipid peroxidation inhibitory. In addition, the amounts of total phenol, ascorbic acid, β-carotene, and lycopene components in the extracts were determined. Among the four mushroom extracts, G. lucidum water extract and G. lucidum ethanol extract showed the highest scavenging activity against DPPH radicals (50% inhibitory concentration = 0.055 ± 0.001 mg/mL). Total phenol was the major antioxidant component found in the mushroom extracts. These results showed that G. lucidum may be used in pharmaceutical applications because of its effective antioxidant properties.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21314365     DOI: 10.1089/jmf.2010.0144

Source DB:  PubMed          Journal:  J Med Food        ISSN: 1096-620X            Impact factor:   2.786


  2 in total

1.  Improving Training Condition Assessment in Endurance Cyclists: Effects of Ganoderma lucidum and Ophiocordyceps sinensis Dietary Supplementation.

Authors:  Paola Rossi; Daniela Buonocore; Elisa Altobelli; Federico Brandalise; Valentina Cesaroni; Davide Iozzi; Elena Savino; Fulvio Marzatico
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-01       Impact factor: 2.629

2.  Antioxidant Potential of Herbal Preparations and Components from Galactites elegans (All.) Nyman ex Soldano.

Authors:  Omar Tebboub; Roberta Cotugno; Feyza Oke-Altuntas; Mohamed Bouheroum; Íbrahim Demirtas; Massimiliano D'Ambola; Nicola Malafronte; Antonio Vassallo
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-16       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.